Loading stock data…
OMDA
$15.29+0.71 (+4.87%)
Market ClosedLast close May 1
Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Omada Health, Inc. in the Healthcare sector is trading at $15.29. The stock is currently 46% below its 52-week high of $28.40, remaining 13.9% below its 200-day moving average. Technical signals show overbought RSI of 80 and bullish MACD crossover, explaining why OMDA maintains its current current market pressure. The Whystock Score of 20/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 80) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$15.29
Potential Upside
5%
Whystock Fair Value$16.05
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Buy
Mean target$21.42+40.1%
Range$14.00 – $30.00
Fundamentals
Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to ad...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$840.87M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-5.56%
Volume
Today's trading volume
1.57M
Recent News
3 Stocks That May Be Undervalued By Up To 46.2%
Over the last 7 days, the United States market has risen by 1.3% and is up 35% over the past year, with earnings expected to grow by 16% annually in the coming years. In this environment of robust growth, identifying stocks that are potentially undervalued can offer opportunities for investors seeking value amidst a rising market.
How The Omda (OB:OMDA) Investment Story Is Shifting As Analyst Expectations Reset
Omda's updated fair value price target of NOK 57.0, trimmed from NOK 59, signals a subtle reset in expectations around what the shares might be worth under current modeling. Street research links this kind of move to a more balanced view of risk and reward, with firms weighing ongoing execution in Q4 and growth efforts against concerns around valuation and sector pressures. As you read on, you will see how to interpret these shifts and keep track of how the analyst story around Omda continues...
Wall Street Analysts Believe Omada Health, Inc. (OMDA) Could Rally 59.53%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 59.5% in Omada Health, Inc. (OMDA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Could This $14 Stock Be Your Ticket to Millionaire Status?
This stock continues to benefit from GLP-1 tailwinds -- and now it trades at a reasonable valuation.
Why Omada Health (OMDA) Is Up 14.4% After First GAAP Profit And GLP-1 Flex Launch
In early March 2026, Omada Health, Inc. reported strong 2025 results with revenue of US$260.21 million, its first GAAP-profitable quarter, and issued 2026 revenue guidance of US$312 million to US$322 million alongside a US$49.57 million shelf registration for 3,644,941 common shares linked to an ESOP offering. The company also introduced GLP-1 Flex Care, a program that lets employees pay cash for obesity medications while receiving coordinated virtual care, giving employers a structured way...